A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin
Eddy Anglade1, Launa J Aspeslet2, Sidney L Weiss11Lux Biosciences Inc., Jersey City, NJ, USA; 2Isotechnika Inc., Edmonton, AB, CanadaAbstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently a...
Enregistré dans:
Auteurs principaux: | Eddy Anglade, Launa J Aspeslet, Sidney L Weiss |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2008
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/801e6176649a4aa99f9d6d2511d1be30 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis
par: Roesel M, et autres
Publié: (2011) -
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
par: Hunter RS, et autres
Publié: (2011) -
Noninfectious uveitis: strategies to optimize treatment compliance and adherence
par: Dolz-Marco R, et autres
Publié: (2015) -
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
par: Jane S Myung, et autres
Publié: (2010) -
A review and update on orphan drugs for the treatment of noninfectious uveitis
par: You C, et autres
Publié: (2017)